Pulmonary Surfactant Preparations and Surfactant Therapy for ARDS in Surgical Intensive Care (a Literature Review)

Introduction. Despite the fact that clinical studies of pulmonary surfactants conducted over many years have demonstrated their efficacy for the treatment of acute respiratory distress syndrome (ARDS) which led to their approval for use inRussia andBelarus, only a few similar positive results have been achieved in other countries. This calls for an extensive literature review for intensive care professionals.

Materials and methods. Using the data from 87 papers this review covers the composition, properties, methods of administration and delivery strategies of surfactant in the treatment and prevention of ARDS in patients with sepsis, severe complex injuries, inhalation injuries and a range of complications associated with thoracic and cardiovascular surgical procedures, massive blood transfusions, severe obstetric pathologies and the A/H1N1 pneumonia.

Results. The early administration of natural pulmonary surfactants within 24 hours following the onset of ARDS as a part of the ARDS combination treatment or prevention drives down the time on mechanical ventilation to six days or shorter, prevents ventilator-associated and hospital-acquired pneumonias, bringing the respiratory failure mortality rate down to 15–20%.

Discussion. Offering the first attempt to discuss the causes of failure of Phase III multicenter clinical trials outsideRussia andBelarus, this review outlines recent developments in synthetic and powdered pulmonary surfactant preparations.

Conclusion. Pulmonary surfactants are highly effective as a part of complex therapy in ARDS treatment and prevention, resulting in two to four fold drop in ARDS mortality rate. The timing of administration is seen as the key factor of the efficacy of surfactant therapy, explaining the differences in clinical trials results from different countries.

1. Clements J.A. Surface tension of lung extracts. Proc Soc Exp Biol Med. 1957;95(1):170–2. DOI: 10.3181/003797279523156

2. King R.J., Clements J.A. Surface active materials from dog lung: composition and physiological correlations. Am J Physiol. 1972;223(3):715– 26. PMID: 506862

3. Bangham A.D. Artificial lung expanding compound (ALECtm). In: Lasic D.D., Papahajopoulos D. (editors). Medical applications of liposomes. Elsevier Science; 1998. P. 452–5. DOI: 10.1016/B9780444829177/500260

4. Schürch S., Goerke J., Clements J.A. Direct determination of volume and time dependence of alveolar surface tension in excised lungs. Proc Natl Acad Sci USA. 1978;75(7):3417–20. PMID: 277943

5. Bonchuk-Dayanikli P., Taeusch W.H. Essential and nonessential constituents of exogenous surfactants. In: Robertson B., Taeusch H.W. (editors). Surfactant therapy for lung disease. Lung biology in health and disease. New York: Marcel Dekker Inc; 1995. P. 217–38.

6. Sanders R.L. The composition of pulmonary surfactant. In: Farrell P.M. (editor). Lung development: Biological and clinical perspectives. New York: Academic Press; 1982. P. 193–210.

7. Possmayer F. A proposed nomenclature for pulmonary surfactant-associated proteins. Am Rev Respir Dis. 1988;138(4):990–8. DOI: 10.1164/ajrccm/138.4.990

8. Knoor A., Gray M.E., Hull W.M., Whitsett J.A., Stahlman M.T. Developmental expression of SP-A and SP-A mRNA in the proximal and distal respiratory epithelium in the human fetus and newborn. J Histochem Cytochem. 1993;41(9):1311–19. PMID: 8354874

9. Rozenberg O.A. Lung surfactant and its use in lung diseases. General Reanimatology. 2007;3(1):66–77 (In Russ.). DOI: 10.15360/1813-97792007-1-66-77

10. Cocksgutt A., Absolom D., Possmayer F. The role of palmitic acid in pulmonary surfactant: enhancement of surface activity and prevention of inhibition by blood proteins. Biochim Biophys Acta. 1991;1085(2):248–56. DOI: 10.1016/00052760(91)90101M

11. Orgeig S., Daniels C.B. The roles of cholesterol in pulmonary surfactant: insights from comparative and evolutionary studies. Comp Biochem Physiol A Mol Integr Physiol. 2001;129(1):75–89. DOI: 10.1016/S10956433(01)00307-5

12. van Iwaarden F.J., van Golde L.M.J. Pulmonary surfactant and lung defense. In: Robertson B., Taeusch H.W. (editors). Surfactant therapy for lung disease. Lung biology in health and disease. New York: Marcel Dekker Inc; 1995. P. 75–84.

13. Phelps D.S. Surfactant regulation of host defense function in the lung: a question of balance. Pediatr Pathol Mol Med. 2001;20(4):269–74. DOI: 10.1080/152279501750412225

14. van Iwaarden J.F., Claassen E., Jeurissen S.H., Haagsman H.P., Kraal G. Alveolar macrophages, surfactant lipids, and surfactant protein B regulate the induction of immune responses via the airways. Am J Respir Cell Mol Biol. 2001;24(4):452–8. DOI: 10.1165/ajrcmb.24.4.4239

15. Ikegami M. SP-B protects lung from inflammation. Appl Cardiopulm Pathophysiol. 2004;13(1):45–7. DOI: 10.1165/rcmb.2002-0071OC

16. Clark H., Palaniyar N., Strong P., Edmondson J., Hawgood S., Reid K.B. Surfactant protein reduces alveolar macrophage apoptosis in vivo. J Immunol. 2002;169(6):2892–9. DOI: 10.4049/jimmunol.169.6.2892

17. Halliday H.L. Surfactants: past, present and future. J Perinatol. 2008;28:47–56. DOI: 10.1038/jp.2008.50

18. Avery M.E., Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child. 1959;97(5Pt1):517–23. DOI: 10.1001/archpedi.1959.02070010519001

19. Northway W.H. Jr, Rosan R.C., Porter D.Y. Pulmonary disease following respiratory therapy of hyaline membrane disease. N Engl J Med. 1967;276:357–68. DOI: 10.1056/NEJM196702162760701

20. Cherukupalli K., Larson J.E., Rotschild A., Thurlbeck WM. Biochemical, clinical, and morphologic studies on lungs of infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 1996;22(4):215–21. PMID: 8905882

21. Ashbaugh D.G., Bigelow D.B., Petty T.L., Levine B.E. Acute respiratory distress in adults. Lancet. 1967;290(7511):319–23. DOI: 10.1016/S01406736(67)90168-7

22. Lewis J.F., Jobe A.H. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis. 1993;147(1):218–33. DOI: 10.1164/ajrccm/147.1.218

23. Schmidt R., Meier U., Yabut Perez M., Walmrath D., Grimminger F., Seeger W., et al. Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and pneumonia. Am J Resp Сrit Care Med. 2001;163(1):95–100. DOI: 10.1164/ajrccm.163.1.9903029

24. Griese M., Birrer P., Demirsoy A. Pulmonary surfactant in cystic fibrosis. Eur Respir J. 1997;10(9):1983–97. DOI: 10.1183/09031936.97.10091983

25. McCormack F.X., King T.E. Jr, Voelker D.R., Robinson P.C., Mason R.J. Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A. Am Rev Respir Dis. 1991;144(1):160–9. DOI: 10.1164/ajrccm/144.1.160

26. Oyarzun M.J., Stevens P., Clemens J.A. Effect of lung collapse on alveolar surfactant in rabbits subjected to unilateral pneumothorax. Exp Lung Res. 1990;15(6):909–24. DOI: 10.3109/01902148909069635

27. Hallman M., Maasilta P., Kivisaari L., Mattson K. Changes in surfactant in bronchoalveolar lavage fluid after hemithorax irradiation in patients with mesothelioma. Am Rev Respir Dis. 1990;141(4 Pt1):998–1007. DOI: 10.1164/ajrccm/141.4_Pt_1.998

28. Hohlfeld J.M., Ahlf K., Enhorning G., Balke K., Erpenbeck V.J., Petschallies J., et.al. Dysfunction of pulmonary surfactant in asthmatics after segmental allergen challenge. Am J Respir Crit Care Med. 1999;159(6):1803–9. DOI: 10.1164/ajrccm.159.6.9806145

29. Devendra G., Spragg R.G. Lung surfactant in subacute pulmonary disease. Respir Res. 2002;3(1):19. DOI: 10.1186/rr168

30. Günther A., Schmidt R., Nix F., Yabut Perez M., Guth C., Rosseau S., et al. Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur Respir J. 1999;14(3):565– 73. DOI: 10.1034/j.13993003.1999.14c14.x

31. Erokhin V.V., Romanova L.K. Pulmonary surfactant system. In: Erokhin V.V., Romanova V.V. (editors). Lung cellular biology in health and disease. A manual for physicians. Moscow: Meditsina Publ.; 2000. P. 167–181 (In Russ.).

32. Fujiwara T., Maeta H., Chida S., Morita T., Watabe Y., Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet. 1980;1(8159):55–9. DOI: 10.1016/S01406736(80)904894

33. Rozenberg O.A. Pulmonary surfactants for acute and chronic lung diseases (Part II). General Reanimatology. 2014;10(5):69–86 (In Russ.). DOI: 10.15360/1813-9779-2014-5-69-86

34. Lachmann B. Surfactant replacement in acute respiratory failure: Animal studies and first clinical trials. In: Lachmann B. (editor). Surfactant replacement therapy. New York: Springer Verlag; 1987. P. 212–20.

35. Spragg R.G. Current status of surfactant treatment of ARDS/ALI. Appl Cardiopulm Pathophysiol. 2004;13(1):88–90.

36. Zil’ber A.P. The syndrome of acute lung injury. In: Zil’ber A.P. Sketches of respiratory medicine. Moscow: MEDpress-inform; 2007. P. 478–530 (In Russ.).

37. Bernard G.R., Artigas A., Brigham K.L., Carlet J., Falke K., Hudson L., et al. The American European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3Pt1):818–24. DOI: 10.1164/ajrccm.149.3.7509706

38. Thompson B.T., Ferguson N.D., Caldwell E., Fan E., Camporota L., Slutsky A.S. Acute respiratory distress syndrome: Berlin definition. JAMA. 2012;307(23):2526–33. DOI: 10.1001/jama.2012.5669

39. Bautin A.E., Rozenberg O.A., Sumin S.A. Acute respiratory distress syndrome In: Sumin S.A., Shapovalov K.G. (editors). Anesthesiology and Reanimatology. Moscow: MIA; 2018. P. 103–19 (In Russ.).

40. Moroz V.V., Golubev A.M. Classification of acute respiratory distress syndrome. General Reanimatology. 2007;3(6):7–9 (In Russ.). DOI: 10.15360/1813-9779-2007-6-7-9

41. Eworuke E., Major J.M., Gilbert McClain L.I. National incidence rates for Acute Respiratory Distress Syndrome (ARDS) and ARDS cause-specific factors in the United States (2006–2014). J Crit Care. 2018;47:192–7. DOI: 10.1016/j.jcrc.2018.07.002

42. Kassil’ V.L., Sapicheva Y.U. Acute respiratory distress syndrome and hypoxemia. Moscow: MEDpress-inform; 2016. 150 p. (In Russ.).

43. Gregory T.J., Steinberg K.P., Spragg R., Gadek J.E., Hyers T.M., Longmore W.J., et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997;155(4):1309–15. DOI: 10.1164/ajrc-cm.155.4.9105072

44. Rosenberg O.A., Bautin A.E., Osovskich V.V., Tsibulkin E.K., Gavrilin S.V., Kozlov I.A., et al. When to start surfactant therapy (STtherapy) of acute lung injury? Eur Respir J. 2001;18(Suppl 38):153.

45. Willson D.F., Thomas N.J., Markovitz B.P., Bauman L.A., DiCarlo J.V., Pon S., et al. Pediatric acute lung injury and sepsis investigators. Effect of exogenous surfactant (Calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA. 2005;293(4):470–6. PMID: 15671432

46. Rodríguez-Moya V.S. Machado-Lubián María del C., Barrese-Pérez Y., Ávila-Albuerne Y., Uranga-Piña R., Blanco-Hidalgo O., et al. Cuban exogenous pulmonary surfactant in treatment of pediatric acute respiratory distress syndrome. Int J Cuban Health Med. 2017;19(2-3):24–31. DOI: 10.1590/medicc.2017.1902030006

47. Anzueto A., Baughman R.P., Guntupalli K.K., Weg J.G., Wiedemann H.P., Raventós A.A., et al. Aerosolized surfactant in adults with septic induced acute respiratory distress syndrome. N Engl J Med. 1996;334(22):1417–21. PMID: 8618579

48. Taeusch H.W., Karen L.U., Ramierez-Schrempp D. Improving pulmonary surfactants. Acta Pharmacol Sin. 2002;11:15–8.

49. Lachmann B. Open up the lung and keep the lung open. Intensive Care Med. 1992;18(6):319–21. DOI: 10.1007/BF01694358

50. Bautin A.E., Osovskikh V.V., Khubulava G.G., Granov D.A., Kozlov I.A., Erokhin V.V., et al. Multicenter clinical trials of surfactantBL for the treatment of adult respiratory distress syndrome. Clinical research of drugs in Russia. 2002;(2):18–23 (In Russ.).

51. Bautin A.E., Naumov A.B., Rubinchik V.E., Osovskikh V.V., Etin V.L., Rosenberg O.A. Applying of the exogenous surfactant in the cardiac surgery clinics of St. Petersburg: from the technology to the evolution of therapeutic strategy. Translational Medicine. 2014;(1):92–7 (In Russ.). DOI: 10.18705/2311-4495-2014-0-1-92-97

52. Moroz V.V., Vlasenko A.V., Golubev A.M., Yakovlev V.N., Alekseyev V.G., Bulatov N.N., et al. The pathogenesis and differential diagnosis of acute respiratory distress syndrome induced by direct and indirect etiological factors. General Reanimatology. 2011;7(3):5 (In Russ.). DOI: 10.15360/1813-9779-2011-3-5

53. Vlasenko A.V., Ostapchenko D.A., Moroz V.V., Rozenberg O.A., Zaks I.O., Linev D.V. Use of Surfactant-BL in adult patients with acute respiratory distress syndrome. General Reanimatology. 2005;1(6):21–9 (In Russ.). DOI: 10.15360/1813-9779-2005-6-21-29

54. Bautin A., Khubulava G., Kozlov I., Poptzov V., Osovskikh V., Seiliev A., et al. Surfactant therapy for patients with ARDS after cardiac surgery. J Liposome Res. 2006;16(3):265–72. DOI: 10.1080/08982100600850997

55. Kozlov I.A., Romanov A.A. Alveolar opening maneuver (mobilization) in intraoperative pulmonary oxygenizing dysfunction in cardiosurgical patients. Russian journal of anesthesiology and reanimatology. 2007;2:27–31 (In Russ.).

56. Kozlov I.A., Poptsov V.N. Combined therapy with nitric oxide and SurfactantBL for acute respiratory distress syndrome after operations using extracorporeal circulation. General Reanimatology. 2005;1(1):15–9 (In Russ.). DOI: 10.15360/1813-9779-2005-1-15-19

57. Shlyk I.V., Krylov K.M., Zueva L.P., Stasova N.B. Epidemiological monitoring in a burn intensive care unit. Infections in Surgery. 2008;6(3):23–8 (In Russ.).

58. Tarasenko M., Shpakov Ig., Kallistov D., Venevetinov Ig., Akulinov E., Tikhonov A., et al. Surfactant therapy — the real chance to survive for the patients with severe inhalation injury. Eur Respir J. 2004;24(Suppl 48):4127.

59. Tarasenko M.Yu., Shpakov I.F., Akulinov E.E., Admakin A.L., Petrachkov S.A., Granov D.A., et al. Treatment option for inhaled lesions. Russian Federation Patent RU 2238757; Jun. 24, 2003 (In Russ.).

60. Pochepen O.N., Zolotuhina L.V., Zemec E.A., Troyanovskiy E.S. The use of surfactant-BL in treatment of inhalation injury after severe burns. Emergency medical care. 2011;12(3):44–7 (In Russ.).

61. Pylaev A.V., Babanin A.A. Use of surfactant replacement therapy in the combination treatment of acute lung injury syndrome in the presence of thermal inhalation injury. Tavricheskiy Mediko-Biologicheskiy Vestnik. 2010;13(4):150–4 (In Russ.).

62. Pallua N., Warbanow K., Noah E.M., Machens H.G., Poets C., Bernhard W., et al. Intrabronchial surfactant application in cases of inhalation injury: First results from patients with severe burns and ARDS. Burns. 1998;24(3):197–206. DOI: 10.1016/S03054179(97)001125

63. Gekkieva O.V., Bautin A.E., Osovskih V.V., Tregubova I.V., Kozetinskij R.A., Sejliev A.A., et al. Preventive treatment with surfactant in thoracic surgeries associated with high risk of respiratory failure. Doktor.Ru. 2016;(12):38–43 (In Russ.).

64. Leone M., Delliaux S., Bourgoin A., Albanese J., Garnier F., Boyadjiev I., et al. Risk factors for late-onset ventilator-associated pneumonia in trauma patients receiving selective digestive decontamination. Intensive Care Med. 2005;16:64–70. DOI: 10.1007/s00134-004-2514-z

65. Forel J., Voillet F., Pulina D. Ventilator-associated pneumonia and ICU mortality in severe ARDS patients ventilated according to a lungprotective strategy. Crit Care. 2012;16:R65. DOI: 10.1186/cc11312

66. Khubutiya M.Sh., Romanov A.A., Kurilova O.A., Timerbayev V.Kh., Pervakova E.I., Poplavsky I.V., et al. Early use of Surfactant-BL after lung transplantation. General Reanimatology. 2013;9(2):12–7 (In Russ.). DOI: 10.15360/1813-9779-2013-2-12-17

67. Cole D.E., Taylor T.L., McCullough D.M., Shoff C.T., Derdak S. Acute respiratory distress syndrome in pregnancy. Crit Care Med. 2005;33(10Suppl):S269–78. PMID: 16215347

68. Kukarskaya I.I., Shvechkova M.V., Kuratsenko I.I., Savva K.N. Experience with Surfactant-BL in obstetric patients with ALJS/ARDS. Medical Science and Education of Ural. 2012;13(1):60–2. (In Russ.).

69. Shvechkova M.V. Clinical features and intensive care of respiratory distress syndrome in obstetrics [dissertation]. Tyumen; 2017 (In Russ.).

70. Napolitano L.M., Park P.K., Raghavendran K., Bartlett R.H. Nonventilatory strategies for patients with life-threatening 2009 А/H1N1 influenza and severe respiratory failure. Crit Care Med. 2010;38(4Suppl):74–90. DOI: 10.1097/CCM.0b013e3181cc5373

71. Novak J. Surfactant treatment for А/H1N1 induces ARDS. In: 14th AllRussian Conference with International Participation on Life Support in Critical Conditions. Moscow; 2012 (In Russ.).

72. Alekseyev A.M., Shupinsky O.V., Khrapov K.N. Intensive therapy in patients with severe influenza A(H1N1) complicated by pneumonia. Messenger of anesthesiology and resuscitation. 2009;6(6):35–9 (In Russ.).

73. Alekseyev A.M., Yakovlev A.A., Shvechkova M.V., Seiliev A.A., Volchkov V.A., Rozenberg A.O. Surfactant therapy for A/H1N1 virusassociated pneumonia and ARDS. Zabaikalskiy Meditsinskiy Zhurnal. 2011;(1):23–7 (In Russ.).

74. Kesecioglu J., Beale R., Stewart T.E., Findlay G.P., Rouby J.J., Holzapfel L., et al. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2009;180(10):989–94. DOI: 10.1164/rccm.200812-1955OC

75. Günther A., Schmidt R., Harodt J., Schmehl T., Walmrath D., Ruppert C., et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact of biophysical and biochemical surfactant properties. Eur Respir J. 2002;19(5):797–804. PMID: 12030716

76. Walmrath D., Grimminger F., Pappert D., Knothe C., Obertacke U., Benzing A., et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J. 2002;19(5):805–10. DOI: 10.1183/09031936.02.00243402

77. Willson D.F., Truwit J.D., Conaway M.R., Traul C.S., Egan E.E., Egan Edmund E. The adult calfactant in acute respiratory distress syndrome trial. Chest. 2015;148(2):356–64. DOI: 10.1378/chest.14-1139

78. Bautin A.E., Solntsev V.N., Naumov A.B., Garifzyanov A.F., Valkovich A.A., Osovskikh V.V., et al. Change in alveolar capillary membrane permeability and in the state of a lung surfactant complex during operations on the heart and aorta. Messenger of anesthesiology and resuscitation. 2010;7(5):11–7 (In Russ.).

79. Oulton M., Fraser M., Dolphin M., Yoon R., Faulkner G. Quantification of surfactant pool sizes in rabbit lung during perinatal development. J Lipid Res.1986;27:602–12. PMID: 3755745

80. Rozenberg O.A., Danilov L.N., Volchkov V.A., Lebedeva E.S., Dubrovskaya V.F., Valkovich A.A., et al. Pharmacological properties and therapeutic effi acy of the domestic preparations of lung surfactants. Bulletin of Experimental Biology and Medicine. 1998;126(10):455–8 (In Russ.).

81. Rozenberg O.A., Sejliev A.A., Granov D.A., Volchkov V.A. The method of obtaining surfactant from cattle. Russian Federation Patent RU 2198670; Fev. 19, 2002 (In Russ.).

82. Grotberg J.B., Filoche M., Willson D.F., Raghavendran K., Notter R.H. Did reduced alveolar delivery of surfactant contribute to negative results in adults with acute respiratory distress syndrome? Am J Respir Crit Care Med. 2017;195(4):538–40. DOI: 10.1164/rccm.201607-1401LE

83. Rosenberg O.A., Bautin A.E., Seiliev A.A. Late start of surfactant therapy and surfactant drug composition as major causes of failure of phase III multi-center clinical trials of surfactant therapy in adults with ARDS. Int J Biomed. 2018;8(3):233–4. DOI: 10.21103/Article8(3)_Lex

84. Kim H.C., Won Y.Y. Clinical, technological, and economic issues associated with developing new lung surfactant therapeutics. Biotech Adv. 2018;36(4):1185–93. DOI: 10.1016/j.biotechadv.2018.03

85. Yong-Sung Choi, Sung-Hoon Chung, Chong-Woo Bae A combination of short and simple surfactant protein B and C analogues as a new synthetic surfactant: in vitro and animal experiments. Yonsei Med J. 2017;58(4):823–8. DOI: 10.3349/ymj.2017.58.4.823

86. Sweet D.G., Turner M.A., Straňák Z., Plavka R., Pau C., Stenson Ben J., et al. A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 2017;102(6):497– 503. DOI: 10.1136/archdischild-2017-312722

87. Walther F.J., Gupta M., Lipp M.M., Chan H., Krzewick J., Gordon L.M., et al. Aerosol delivery of dry powder synthetic lung surfactant to surfactant-deficient rabbits and preterm lambs on non-invasive respiratory support. Gates Open Research. 2019;3:6. DOI: 10.12688/gatesopenres.12899.1